Immunotherapy Combo Offers Slight Survival Benefit in Melanoma.
Data on 2-year survival in the phase III CheckMate 067 trial testing nivolumab plus ipilimumab showed a slight survival benefit for the combination over nivolumab monotherapy-but the difference may not be dramatic enough to justify using the combination given the added side effects.